News & Media

Kane Biotech in the News

In January, Kane Biotech was featured in several news media articles, including  BNN Bloomberg and Benzinga, as well as a podcast with Kane is engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms.

With a portfolio of biotechnologies, intellectual property (80 patents and patents pending), Kane’s coactiv+™ Antimicrobial Wound Gel will be Kane’s first wound product introduced to the global market and will create a new revenue stream supplementing existing revenues from Kane’s animal health and dermatology units.


Kane Biotech 01.jpg (98 KB)


Chronic wounds are defined as “wounds that fail to proceed through the normal phases of wound healing in an orderly and timely manner,” chronic wounds range from severe burns to bedsores to diabetic ulcers. Whatever the cause, they all carry costs in medical care as well as pain and decreased quality of life, and many can be attributed to something you may have never heard of: biofilms.

“Biofilms are formed when bacteria and/or fungi adhere to surfaces and excrete a glue-like substance that acts as an anchor and provides protection from the environment,” making “bacteria up to 1,000 times more resistant to antibiotics, antimicrobial agents, disinfectants and the host immune system,” according to Kane Biotech Inc. (TSX-V:KNE | OTCQB:KNBIF).

Kane’s latest product, coactiv+™ Antimicrobial Hydrogel, is designed to address biofilms and the problems they cause in chronic wounds — and at a price that will allow it to be covered by Medicare in the U.S. as well as insurers around the globe, a crucial distinction for a premium product. Read the article in full: Biotech innovator combats the largest unresolved problem in wound care – BNN Bloomberg


placeholder.jpg (33 KB)

Kane Biotech President & CEO Marc Edwards joined Natalie Stoberman from the Proactive newsroom to share more details behind the first distribution agreement for its coactiv+™ Antimicrobial Hydrogel.

Edwards says Kane Biotech the agreement with Salud Pharma is a significant milestone to secure global partners and bring its technologies to the wound care and surgical markets.

The coactiv+™ Antimicrobial Hydrogel is a combination of Kane’s patented coactiv+™ antibiofilm technology and PHMB in a thermo-reversible gel. The combination of these three components provides for a moist environment best suited for wound healing, with superior anti-microbial activity in an easy-to-use thermo-reversible gelling system that is optimized for sensitive wounds. Watch the full interview here: Kane Biotech announces distribution agreement for coactiv+ Antimicrobial Hydrogel (

Kane Biotech coactiv+.png (176 KB)

Kane Biotech is listed on the TSX Venture Exchange under the symbol “KNE” and on the OTCQB Venture Market under the symbol “KNBIF”.

News source: Kane Biotech



Subscribe to the BAM Newsletter

Sign up for one of BAM's newsletter to learn more about bioscience, happenings in Manitoba's bioeconomy, industry conferences, and BAM training events.